Avicanna (AVCN) Status Update summary

Business pillars and portfolio expansion

• Four commercial pillars: RHO Phyto (medical products), MyMedi (medical cannabis platform), pharmaceutical pipeline, and Aureus (API/raw materials).

• Portfolio in Canada expanded from 42 to 52 SKUs, a 24% increase, with broader distribution and new medical channels.

• RHO Phyto remains the flagship, offering 30 proprietary SKUs with various cannabinoid ratios, now including minor cannabinoids.

• Aureus division in Colombia now exports GACP and organic certified flower, with initial exports to Switzerland and plans for Europe and Australia.

• Strategic collaborations with Fortune 100/500 and leading cannabis companies, plus M&A activity to support growth.

R&D, clinical, and intellectual property advancements

• Over 30 R&D preclinical and clinical trials conducted with leading Canadian institutions.

• New technologies commercialized: deep tissue gel and spray, Influit (self-emulsifying system), and PwdRx (powder delivery), with patents filed and promising preclinical data.

• National real-world evidence study and phase II RCT for osteoarthritic pain underway, reinforcing scientific rigor.

• Expanded patent portfolio, including a new US patent for a dermatology topical and filings for PwdRx technology.

Medical platform and education initiatives

• MyMedi platform enhanced with expanded patient support, insurance processing, and clinical guidelines.

• Avicenna Academy grew to over 25 presentations, offering practical, evidence-based education for clinicians.

• Morpheus patient intelligence platform provides deep insights into patient, product, and clinical outcomes, informing product development.

• Hosted a symposium with 400+ medical professionals, establishing an industry-standard forum for cannabinoid research.